Emmaus Life Sciences (NASDAQ:EMMA) CEO Yutaka Niihara purchased 48,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were purchased at an average cost of $1.89 per share, for a total transaction of $90,720.00.
Yutaka Niihara also recently made the following trade(s):
- On Tuesday, February 18th, Yutaka Niihara acquired 22,750 shares of Emmaus Life Sciences stock. The stock was purchased at an average cost of $1.72 per share, with a total value of $39,130.00.
- On Wednesday, February 12th, Yutaka Niihara acquired 31,100 shares of Emmaus Life Sciences stock. The stock was acquired at an average price of $1.75 per share, with a total value of $54,425.00.
- On Friday, February 7th, Yutaka Niihara acquired 18,800 shares of Emmaus Life Sciences stock. The stock was acquired at an average price of $1.70 per share, with a total value of $31,960.00.
Shares of EMMA stock traded up $0.86 during trading hours on Friday, hitting $2.77. The stock has a market capitalization of $134.27 million, a price-to-earnings ratio of -0.25 and a beta of 2.91. The stock’s fifty day moving average is $2.29 and its 200-day moving average is $2.82. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.37. Emmaus Life Sciences has a 1 year low of $0.95 and a 1 year high of $11.76.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.
Featured Article: What is Forex?
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.